Cytokinetics Launches Myqorzo in EU, but Bearish Case Hinges on U.S. Uptake

What happened

Cytokinetics announced the first commercial launch of Myqorzo (aficamten) in Germany, marking its EU entry for obstructive HCM. While this expands the addressable market, the launch follows a strong U.S. start but faces entrenched competition from Bristol Myers Squibb's Camzyos, which has treated over 12,500 patients. The company's valuation (~$7.7B) remains heavily dependent on rapid U.S. share gains and positive ACACIA nHCM data in Q2 2026, yet its balance sheet is strained with negative equity and royalty burdens. Management's ability to convert EU launches into meaningful revenue is unproven, and partner execution (Sanofi/Bayer) introduces additional risk. Thus, the EU launch is a positive step but does not alleviate the core concerns about Myqorzo's competitive positioning and financial sustainability.

Implication

For investors, the EU launch is a tactical positive but does not alter the fundamental thesis that Myqorzo must rapidly capture share from Camzyos in the U.S. to justify the current valuation. The company's heavy cost structure and complex financing (royalties, converts) mean that any shortfall in U.S. sales or failure in ACACIA could trigger significant dilution. Given the crowded bullish sentiment and insider selling near highs, we view this as an opportunity to reduce positions or trim. Until concrete U.S. launch metrics (patient starts, payer coverage) emerge above consensus, the risk of disappointment remains elevated. The EU launch may provide a short-term sentiment boost, but the long-term investment case still hinges on Q2 2026 ACACIA data and sustained U.S. Myqorzo adoption. We maintain a cautious stance with a potential sell rating, advising entry near $50 and trim above $80.

Thesis delta

The EU launch incrementally de-risks Myqorzo's ex-U.S. revenue potential but does not materially shift the risk/reward calculus. The core debate remains whether Myqorzo can achieve high single-digit U.S. market share within 12–18 months; today’s news does not change that. If U.S. launch metrics disappoint, the EU revenue will not compensate for the valuation skew to the downside.